間充質干細胞治療急性呼吸窘迫綜合征的研究進展及相關問題_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

朱婕 ,  郭述良

重慶醫科大學附屬第一醫院呼吸與危重癥醫學科（重慶 ?400016）;

Corresponding?author：

郭述良, Email: GUOSL999@sina.com

Keywords：

DOI：

10.7507/1671-6205.201608014

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 朱婕, 郭述良. 間充質干細胞治療急性呼吸窘迫綜合征的研究進展及相關問題. Chinese Journal of Respiratory and Critical Care Medicine, 2017, 16(2): 191-196. doi: 10.7507/1671-6205.201608014 Copy

1.	Tsushima K, King LS, Aggarwal NR, et al. Acute lung injury review. Intern Med, 2009, 48(9): 621-630.
2.	劉安, 陳余清, 沈園兵. 間充質干細胞在急性肺損傷/急性呼吸窘迫綜合征中的應用研究進展. 國際呼吸雜志, 2012, 32(19): 1497-1501.
3.	Meirelles Lda S, Fontes AM, Covas DT, et al. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev, 2009, 20(5-6): 419-427.
4.	Liu WH, Liu JJ, Wu J, et al. Novel mechanism of inhibition of dendritic cells maturation by mesenchymal stem cells via interleukin-10 and the JAK1/STAT3 signaling pathway. PloS One, 2013, 8(1): e55487.
5.	Bai LH, Lennon DP, Caplan AI, et al. Hepatocyte growth factor mediates mesenchymalstem cell-induced recovery in multiplesclerosis models. Nat Neurosci, 2012, 15(6): 862-870.
6.	Voulgari-Kokota A, Fairless R, Karamita M, et al. Mesenchymal stem cells protect CNS neurons against glutamate excitotoxicity by inhibiting glutamate receptor expression and function. Exp Neurol, 2012, 236(1): 161-170.
7.	Constantin G, Marconi S, Rossi B, et al. Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells, 2009, 27(10): 2624-2635.
8.	Coulson-Thomas VJ, Gesteira TF, Hascall V, et al. Umbilical cord mesenchymal stem cells suppress host rejection: the role of the glycocalyx. J Biol Chem, 2014, 289(34): 23465-23481.
9.	Akyurekli C, Le Y, Richardson RB, et al. A systematic review of preclinical studies on the therapeutic potential of mesenchymal stromal cell-derived microvesicles. Stem Cell Rev, 2015, 11(1): 150-160.
10.	Corrado C, Raimondo S, Chiesi A, et al. Exosomes as intercellular signaling organelles involved in health and disease: basic science and clinical applications. Int J Mol Sci, 2013, 14(3): 5338-5366.
11.	Baglio SR, Pegtel DM, Baldini N. Mesenchymal stem cell secreted vesicles provide novel opportunities in (stem) cell-free therapy. Front Physiol, 2012, 3: 359.
12.	Taylor DD, Gercel-Taylor C. Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments. Semin Immunopathol, 2011, 33(5): 441-454.
13.	Bobrie A, Colombo M, Raposo G, et al. Exosome secretion: molecular mechanisms and roles in immune responses. Traffic, 2011, 12(12): 1659-1668.
14.	Zhang B, Yin Y, Lai RC, et al. Mesenchymal stem cells secrete immunologically active exosomes. Stem Cells Devel, 2014, 23(11): 1233-1244.
15.	Budoni M, Fierabracci A, Luciano R, et al. The immunosuppressive effect of mesenchymal stromal cells on B lymphocytes is mediated by membrane vesicles. Cell Transplant, 2013, 22(2): 369-379.
16.	Lee C, Mitsialis SA, Aslam M, et al. Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia induced pulmonary hypertension. Circulation, 2012, 126(22): 2601-2611.
17.	Sdrimas K, Kourembanas S. MSC microvesicles for the treatment of lung disease: a new paradigm for cell-free therapy. Antioxid Redox Signal, 2014, 21(13): 1905-1915.
18.	Zhu YG, Feng XM, Abbott J, et al. Human mesenchymal stem cell microvesicles for treatment of Escherichia coli endotoxin induced acute lung injury in mice. Stem Cells, 2014, 32(1): 116-125.
19.	Kassmer SH, Krause DS. Detection of bone marrow-derived lung epithelial cells. Exp Hematol, 2010, 38(7): 564-573.
20.	Spees JL, Whitney MJ, Sullivan DE, et al. Bone marrow progenitor cells contribute to repair and remodeling of the lung and heart in a rat model of progressive pulmonary hypertension. FASEB J, 2008, 22(4): 1226-1236.
21.	Sueblinvong V, Loi R, Eisenhauer PL, et al. Derivation of lung epithelium from human cord blood-derived mesenchymal stem cells. Am J Respir Crit Care Med, 2008, 177(7): 701-711.
22.	T?gel F, Hu Z, Weiss K, et al. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol, 2005, 289(1): F31-F42.
23.	T?gel F, Weiss K, Yang Y, et al. Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to therecovery from acute kidney injury. Am J Physiol Renal Physiol, 2007, 292(5): F1626-F1635.
24.	Maggini J, Mirkin G, Bognanni I, et al. Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. PLoS One, 2010, 5(2): e9252.
25.	Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol, 2012, 12(5): 383-396.
26.	Akiyama K, Chen C, Wang D, et al. Mesenchymal stem cell-induced immunoregulation involves Fas ligand/Fas-mediated T cell apoptosis. Cell Stem Cell, 2012, 10(5): 544-555.
27.	Bianco P. " Mesenchymal” stem cells. Annu Rev Cell Dev Biol, 2014, 30: 677-704.
28.	Chen X, Shao H, Zhi Y, et al. CD73 pathway contributes to the immunosuppressive ability of mesenchymal stem cells in intraocular autoimmune responses. Stem Cells Dev, 2016, 25(4): 337-346.
29.	Franquesa M, Hoogduijn MJ, Bestard O, et al. Immunomodulatory effect of mesenchymal stem cells on B cells. Front Immunol, 2012, 3: 212.
30.	Song X, Xie S, Lu K, et al. Mesenchymal stem cells alleviate experimental asthma by inducing polarization of alveolar macrophages. Inflammation, 2015, 38(2): 485-492.
31.	Khan I, Zhang L, Mohammed M, et al. Effects of Wharton's jelly-derived mesenchymal stem cells on neonatal neutrophils. J Inflamm Res, 2015, 8(1): 1-8.
32.	Mohammadpour H, Pourfathollah AA, Zarif MN, et al. TNF-α modulates the immunosuppressive effects of MSCs on dendritic cells and T cells. Int Immunopharmacol, 2015, 28(2): 1009-1017.
33.	Consentius C, Akyuz L, Schmidt-Lucke JA, et al. Mesenchymal stromal cells prevent allostimulation in vivo and control checkpoints of Th1 priming: migration of human DC to lymph nodes and NK cell activation. Stem Cells, 2015, 33(10): 3087-3099.
34.	Abomaray FM, Al Jumah MA, Kalionis B, et al. Human chorionic villous mesenchymal stem cells modify the functions of human dendritic cells, and induce an anti-inflammatory phenotype in CD1+ dendritic cells. Stem Cell Rev, 2015, 11(3): 423-441.
35.	Qu M, Cui J, Zhu J, et al. Bone marrow-derived mesenchymal stem cells suppress NK cell recruitment and activation in PolyI:C-induced liver injury. Biochem Biophys Res Commun, 2015, 466(2): 173-179.
36.	Lu Y, Liu J, Liu Y, et al. TLR4 plays a crucial role in MSC-induced inhibition of NK cell function. Biochem Biophys Res Commun, 2015. 464(2): 541-547.
37.	Coulson-Thomas VJ, Coulson-Thomas YM, Gesteira TF, et al. Extrinsic and intrinsic mechanisms by which mesenchymal stem cells suppress the immune system. Ocul Surf, 2016, 14(2): 121-134.
38.	Fran?ois M, Romieu-Mourez R, Li M, et al. Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther, 2012, 20(1): 187-195.
39.	Croitoru-Lamoury J, Lamoury FM, Caristo M, et al. Interferon-γ regulates the proliferation and differentiation of mesenchymal stem cells via activation of indoleamine 2,3 dioxygenase ll(IDO). PLoS One, 2011, 6(2): e14698.
40.	Waterman RS, Tomchuck SL, Henkle SL, et al. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype. PloS One, 2010, 5(4): e10088.
41.	Schraufstatter IU, Discipio RG., Zhao M, et al. C3a and C5a are chemotactic factors for human mesenchymal stem cells, which cause prolonged ERK1/2 phosphorylation. J Immunol, 2009, 182(6): 3827-3836.
42.	Lee JW, Krasnodembskaya A, McKenna DH, et al. Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria. Am J Respir Crit Care Med, 2013; 187(7): 751-760.
43.	Curley GF, McAuley DF. Stem cells for respiratory failure. Curr Opin Crit Care, 2015, 21(1): 42-49.
44.	Toonkel RL, Hare JM, Matthay MA, et al. Mesenchymal stem cells and idiopathic pulmonary fibrosis. Potential for clinical testing. Am J Respir Crit Care Med, 2013, 188(2): 133-140.
45.	Rojas M, Xu J, Woods CR, et al. Bone marrow- derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol, 2005, 33(2): 145-152.
46.	Ortiz LA, Dutreil M, Fattman C, et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci U S A, 2007, 104(26): 11002-11007.
47.	Yilmaz G, Vital S, Yilmaz CE, et al. Selectin-mediated recruitment of bone marrow stromal cells in the postischemic cerebral microvasculature. Stroke, 2011, 42(3): 806-811.
48.	Hung SC, Pochampally RR, Chen SC, et al. Angiogenic effects of human multipotent stromal cell conditioned medium activate the PI3K-Akt pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and stimulate angiogenesis. Stem Cells, 2007, 25(9): 2363-2370.
49.	Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell, 2013, 13(4): 392-402.
50.	Prockop DJ, Oh JY. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol Ther, 2012, 20(1): 14-20.
51.	Ranganath SH, Levy O, Inamdar MS, et al. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell, 2012, 10(3): 244-258.
52.	Mei SH, McCarter SD, Deng Y, et al. Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS Med, 2007, 4(9): e269.
53.	He HL, Liu L, Chen QH, et al. MSCs modified with ACE2 restore endothelial function following LPS challenge by inhibiting the activation of RAS. J Cell Physiol, 2015, 230(3): 691-701.
54.	Min F, Gao F, Li Q, et al.: Therapeutic effect of human umbilical cord mesenchymal stem cells modified by angiotensin-converting enzyme 2 gene on bleomycin-induced lung fibrosis injury. Mol Med Rep, 2015, 11(4): 2387-2396.
55.	Martinez-Gonzalez I, Roca O, Masclans JR, et al. Human mesenchymal stem cells overexpressing the IL-33 antagonist soluble IL-1 receptor-like-1 attenuate endotoxin-induced acute lung injury. Am J Respir Cell Mol Biol, 2013, 49(4): 552-562.
56.	Mias C, Trouche E, Seguelas MH, et al. Ex vivo pretreatment with melatonin improves survival, proangiogenic/mitogenic activity, and efficiency of mesenchymal stem cells injected into ischemic kidney. Stem Cells, 2008, 26(7): 1749-1757.
57.	Ranganath SH, Tong ZX, Levy O, et al. Controlled inhibition of the mesenchymal stromal cell pro-inflammatory secretome via microparticle engineering. Stem Cell Reports, 2016, 6(6): 926-939.
58.	Weiss DJ, Casaburi R, Flannery R, et al. A placebo controlled, randomized trial of mesenchymal stem cells in COPD. Chest, 2013, 143(6): 1590-1598.
59.	Wilson JG, Liu KD, Zhuo HJ, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med, 2015, 3(1): 24-32.
60.	Zheng G, Huang L, Tong H, et al.: Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. Respir Res, 2014, 15(1): 39.
61.	Chapel A, Bertho JM, Bensidhoum M, et al. Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome. J Gene Med, 2003, 5(12): 1028-1038.
62.	Devine SM, Cobbs C, Jennings M, et al. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood, 2003, 101(8): 2999-3001.
63.	Gholamrezanezhad A, Mirpour S, Bagheri M, et al. In vivo tracking of ¹¹¹In-oxine labeled mesenchymal stem cells following infusion in patients with advanced cirrhosis. Nucl Med Biol, 2011, 38(7): 961-967.
64.	Leibacher J, Henschler R. Biodistribution. migration and homing of systemically applied mesenchymal stem/stromal cells. Stem Cell Res Ther, 2016, 7(1): 7.
65.	Thankamony SP, Sackstein R. Enforced hematopoietic cell E- and L-selectin ligand (HCELL) expression primes transendothelial migration of human mesenchymal stem cells. Proc Natl Acad Sci U S A, 2011, 108(6): 2258-2263.
66.	Wu M, Ji S, Xiao S, et al. JAM-A promotes wound healing by enhancing both homing and secretion activities of mesenchymal stem cells. Clin Sci (Lond), 2015, 129(7): 575-588.
67.	Li Q, Zhang A, Tao C, et al. The role of SDF-1-CXCR4/CXCR7 axis in biological behaviors of adipose tissue-derived mesenchymal stem cells in vitro. Biochem Biophys Res Commun, 2013, 441(3): 675-680.
68.	Francois M, Romieu-Mourez R, Li M, et al. Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther, 2011, 20(1): 187-195.
69.	Xu S, Menu E, De Becker A, et al. Bone marrow-derived mesenchymal stromal cells are attracted by multiple myeloma cell-produced chemokine CCL25 and favor myeloma cell growth in vitro and in vivo. Stem Cells, 2012, 30(2): 266-279.
70.	Won YW, Patel AN, Bull DA. Cell surface engineering to enhance mesenchymal stem cell migration toward an SDF-1 gradient. Biomaterials, 2014, 35(21): 5627-5635.
71.	De Becker A, Riet IV. Homing and migration of mesenchymal stromal cells: how to improve the efficacy of cell therapy? World J Stem Cells, 2016, 8(3): 73-87.
72.	Lalu M, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One, 2012, 7(10): e47559.
73.	von Bahr L, Batsis I, Moll G, et al. Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. Stem Cells, 2012, 30(7): 1575-1578.
74.	Liu R, Wei S, Chen J, et al. Mesenchymal stem cells in lung cancer tumor microenvironment: their biological properties, influence on tumor growth and therapeutic implications. Cancer Lett, 2014, 353(2): 145-152.
75.	Vulcano F, Milazzo L, Ciccarelli C, et al. Wharton's jelly mesenchymal stromal cells have contrasting effects on proliferation and phenotype of cancer stem cells from different subtypes of lung cancer. Exp Cell Res, 2016, 345(2): 190-198.
76.	Nystedt J, Anderson H, Tikkanen J, et al. Cell surface structures influence lung clearance rate of systemically infused mesenchymal stromal cells. Stem Cells, 2013, 31(2): 317-326.
77.	Pilz GA, Ulrich C, Ruh M, et al. Human term placenta-derived mesenchymal stromal cells are less prone to osteogenic differentiation than bone marrow-derived mesenchymal stromal cells. Stem Cells Dev, 2011, 20(4): 635-646.
78.	Elahi KC, Klein G, Avci-Adali M, et al. Human mesenchymal stromal cells from different sources diverge in their expression of cell surface proteins and display distinct differentiation patterns. Stem Cells Int, 2016: 5646384.
79.	Rolandsson Enes S, Andersson Sj?land A, Skog I, et al. MSC from fetal and adult lungs possess lung-specific properties compared to bone marrow-derived MSC. Sci Rep, 2016, 6: 29160.
80.	Strioga M, Viswanathan S, Darinskas A, et al. Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. Stem Cells Dev, 2012, 21(14): 2724-2752.

1. Tsushima K, King LS, Aggarwal NR, et al. Acute lung injury review. Intern Med, 2009, 48(9): 621-630.
2. 劉安, 陳余清, 沈園兵. 間充質干細胞在急性肺損傷/急性呼吸窘迫綜合征中的應用研究進展. 國際呼吸雜志, 2012, 32(19): 1497-1501.
3. Meirelles Lda S, Fontes AM, Covas DT, et al. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev, 2009, 20(5-6): 419-427.
4. Liu WH, Liu JJ, Wu J, et al. Novel mechanism of inhibition of dendritic cells maturation by mesenchymal stem cells via interleukin-10 and the JAK1/STAT3 signaling pathway. PloS One, 2013, 8(1): e55487.
5. Bai LH, Lennon DP, Caplan AI, et al. Hepatocyte growth factor mediates mesenchymalstem cell-induced recovery in multiplesclerosis models. Nat Neurosci, 2012, 15(6): 862-870.
6. Voulgari-Kokota A, Fairless R, Karamita M, et al. Mesenchymal stem cells protect CNS neurons against glutamate excitotoxicity by inhibiting glutamate receptor expression and function. Exp Neurol, 2012, 236(1): 161-170.
7. Constantin G, Marconi S, Rossi B, et al. Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells, 2009, 27(10): 2624-2635.
8. Coulson-Thomas VJ, Gesteira TF, Hascall V, et al. Umbilical cord mesenchymal stem cells suppress host rejection: the role of the glycocalyx. J Biol Chem, 2014, 289(34): 23465-23481.
9. Akyurekli C, Le Y, Richardson RB, et al. A systematic review of preclinical studies on the therapeutic potential of mesenchymal stromal cell-derived microvesicles. Stem Cell Rev, 2015, 11(1): 150-160.
10. Corrado C, Raimondo S, Chiesi A, et al. Exosomes as intercellular signaling organelles involved in health and disease: basic science and clinical applications. Int J Mol Sci, 2013, 14(3): 5338-5366.
11. Baglio SR, Pegtel DM, Baldini N. Mesenchymal stem cell secreted vesicles provide novel opportunities in (stem) cell-free therapy. Front Physiol, 2012, 3: 359.
12. Taylor DD, Gercel-Taylor C. Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments. Semin Immunopathol, 2011, 33(5): 441-454.
13. Bobrie A, Colombo M, Raposo G, et al. Exosome secretion: molecular mechanisms and roles in immune responses. Traffic, 2011, 12(12): 1659-1668.
14. Zhang B, Yin Y, Lai RC, et al. Mesenchymal stem cells secrete immunologically active exosomes. Stem Cells Devel, 2014, 23(11): 1233-1244.
15. Budoni M, Fierabracci A, Luciano R, et al. The immunosuppressive effect of mesenchymal stromal cells on B lymphocytes is mediated by membrane vesicles. Cell Transplant, 2013, 22(2): 369-379.
16. Lee C, Mitsialis SA, Aslam M, et al. Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia induced pulmonary hypertension. Circulation, 2012, 126(22): 2601-2611.
17. Sdrimas K, Kourembanas S. MSC microvesicles for the treatment of lung disease: a new paradigm for cell-free therapy. Antioxid Redox Signal, 2014, 21(13): 1905-1915.
18. Zhu YG, Feng XM, Abbott J, et al. Human mesenchymal stem cell microvesicles for treatment of Escherichia coli endotoxin induced acute lung injury in mice. Stem Cells, 2014, 32(1): 116-125.
19. Kassmer SH, Krause DS. Detection of bone marrow-derived lung epithelial cells. Exp Hematol, 2010, 38(7): 564-573.
20. Spees JL, Whitney MJ, Sullivan DE, et al. Bone marrow progenitor cells contribute to repair and remodeling of the lung and heart in a rat model of progressive pulmonary hypertension. FASEB J, 2008, 22(4): 1226-1236.
21. Sueblinvong V, Loi R, Eisenhauer PL, et al. Derivation of lung epithelium from human cord blood-derived mesenchymal stem cells. Am J Respir Crit Care Med, 2008, 177(7): 701-711.
22. T?gel F, Hu Z, Weiss K, et al. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol, 2005, 289(1): F31-F42.
23. T?gel F, Weiss K, Yang Y, et al. Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to therecovery from acute kidney injury. Am J Physiol Renal Physiol, 2007, 292(5): F1626-F1635.
24. Maggini J, Mirkin G, Bognanni I, et al. Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. PLoS One, 2010, 5(2): e9252.
25. Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol, 2012, 12(5): 383-396.
26. Akiyama K, Chen C, Wang D, et al. Mesenchymal stem cell-induced immunoregulation involves Fas ligand/Fas-mediated T cell apoptosis. Cell Stem Cell, 2012, 10(5): 544-555.
27. Bianco P. " Mesenchymal” stem cells. Annu Rev Cell Dev Biol, 2014, 30: 677-704.
28. Chen X, Shao H, Zhi Y, et al. CD73 pathway contributes to the immunosuppressive ability of mesenchymal stem cells in intraocular autoimmune responses. Stem Cells Dev, 2016, 25(4): 337-346.
29. Franquesa M, Hoogduijn MJ, Bestard O, et al. Immunomodulatory effect of mesenchymal stem cells on B cells. Front Immunol, 2012, 3: 212.
30. Song X, Xie S, Lu K, et al. Mesenchymal stem cells alleviate experimental asthma by inducing polarization of alveolar macrophages. Inflammation, 2015, 38(2): 485-492.
31. Khan I, Zhang L, Mohammed M, et al. Effects of Wharton's jelly-derived mesenchymal stem cells on neonatal neutrophils. J Inflamm Res, 2015, 8(1): 1-8.
32. Mohammadpour H, Pourfathollah AA, Zarif MN, et al. TNF-α modulates the immunosuppressive effects of MSCs on dendritic cells and T cells. Int Immunopharmacol, 2015, 28(2): 1009-1017.
33. Consentius C, Akyuz L, Schmidt-Lucke JA, et al. Mesenchymal stromal cells prevent allostimulation in vivo and control checkpoints of Th1 priming: migration of human DC to lymph nodes and NK cell activation. Stem Cells, 2015, 33(10): 3087-3099.
34. Abomaray FM, Al Jumah MA, Kalionis B, et al. Human chorionic villous mesenchymal stem cells modify the functions of human dendritic cells, and induce an anti-inflammatory phenotype in CD1+ dendritic cells. Stem Cell Rev, 2015, 11(3): 423-441.
35. Qu M, Cui J, Zhu J, et al. Bone marrow-derived mesenchymal stem cells suppress NK cell recruitment and activation in PolyI:C-induced liver injury. Biochem Biophys Res Commun, 2015, 466(2): 173-179.
36. Lu Y, Liu J, Liu Y, et al. TLR4 plays a crucial role in MSC-induced inhibition of NK cell function. Biochem Biophys Res Commun, 2015. 464(2): 541-547.
37. Coulson-Thomas VJ, Coulson-Thomas YM, Gesteira TF, et al. Extrinsic and intrinsic mechanisms by which mesenchymal stem cells suppress the immune system. Ocul Surf, 2016, 14(2): 121-134.
38. Fran?ois M, Romieu-Mourez R, Li M, et al. Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther, 2012, 20(1): 187-195.
39. Croitoru-Lamoury J, Lamoury FM, Caristo M, et al. Interferon-γ regulates the proliferation and differentiation of mesenchymal stem cells via activation of indoleamine 2,3 dioxygenase ll(IDO). PLoS One, 2011, 6(2): e14698.
40. Waterman RS, Tomchuck SL, Henkle SL, et al. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype. PloS One, 2010, 5(4): e10088.
41. Schraufstatter IU, Discipio RG., Zhao M, et al. C3a and C5a are chemotactic factors for human mesenchymal stem cells, which cause prolonged ERK1/2 phosphorylation. J Immunol, 2009, 182(6): 3827-3836.
42. Lee JW, Krasnodembskaya A, McKenna DH, et al. Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria. Am J Respir Crit Care Med, 2013; 187(7): 751-760.
43. Curley GF, McAuley DF. Stem cells for respiratory failure. Curr Opin Crit Care, 2015, 21(1): 42-49.
44. Toonkel RL, Hare JM, Matthay MA, et al. Mesenchymal stem cells and idiopathic pulmonary fibrosis. Potential for clinical testing. Am J Respir Crit Care Med, 2013, 188(2): 133-140.
45. Rojas M, Xu J, Woods CR, et al. Bone marrow- derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol, 2005, 33(2): 145-152.
46. Ortiz LA, Dutreil M, Fattman C, et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci U S A, 2007, 104(26): 11002-11007.
47. Yilmaz G, Vital S, Yilmaz CE, et al. Selectin-mediated recruitment of bone marrow stromal cells in the postischemic cerebral microvasculature. Stroke, 2011, 42(3): 806-811.
48. Hung SC, Pochampally RR, Chen SC, et al. Angiogenic effects of human multipotent stromal cell conditioned medium activate the PI3K-Akt pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and stimulate angiogenesis. Stem Cells, 2007, 25(9): 2363-2370.
49. Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell, 2013, 13(4): 392-402.
50. Prockop DJ, Oh JY. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol Ther, 2012, 20(1): 14-20.
51. Ranganath SH, Levy O, Inamdar MS, et al. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell, 2012, 10(3): 244-258.
52. Mei SH, McCarter SD, Deng Y, et al. Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS Med, 2007, 4(9): e269.
53. He HL, Liu L, Chen QH, et al. MSCs modified with ACE2 restore endothelial function following LPS challenge by inhibiting the activation of RAS. J Cell Physiol, 2015, 230(3): 691-701.
54. Min F, Gao F, Li Q, et al.: Therapeutic effect of human umbilical cord mesenchymal stem cells modified by angiotensin-converting enzyme 2 gene on bleomycin-induced lung fibrosis injury. Mol Med Rep, 2015, 11(4): 2387-2396.
55. Martinez-Gonzalez I, Roca O, Masclans JR, et al. Human mesenchymal stem cells overexpressing the IL-33 antagonist soluble IL-1 receptor-like-1 attenuate endotoxin-induced acute lung injury. Am J Respir Cell Mol Biol, 2013, 49(4): 552-562.
56. Mias C, Trouche E, Seguelas MH, et al. Ex vivo pretreatment with melatonin improves survival, proangiogenic/mitogenic activity, and efficiency of mesenchymal stem cells injected into ischemic kidney. Stem Cells, 2008, 26(7): 1749-1757.
57. Ranganath SH, Tong ZX, Levy O, et al. Controlled inhibition of the mesenchymal stromal cell pro-inflammatory secretome via microparticle engineering. Stem Cell Reports, 2016, 6(6): 926-939.
58. Weiss DJ, Casaburi R, Flannery R, et al. A placebo controlled, randomized trial of mesenchymal stem cells in COPD. Chest, 2013, 143(6): 1590-1598.
59. Wilson JG, Liu KD, Zhuo HJ, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med, 2015, 3(1): 24-32.
60. Zheng G, Huang L, Tong H, et al.: Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. Respir Res, 2014, 15(1): 39.
61. Chapel A, Bertho JM, Bensidhoum M, et al. Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome. J Gene Med, 2003, 5(12): 1028-1038.
62. Devine SM, Cobbs C, Jennings M, et al. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood, 2003, 101(8): 2999-3001.
63. Gholamrezanezhad A, Mirpour S, Bagheri M, et al. In vivo tracking of ¹¹¹In-oxine labeled mesenchymal stem cells following infusion in patients with advanced cirrhosis. Nucl Med Biol, 2011, 38(7): 961-967.
64. Leibacher J, Henschler R. Biodistribution. migration and homing of systemically applied mesenchymal stem/stromal cells. Stem Cell Res Ther, 2016, 7(1): 7.
65. Thankamony SP, Sackstein R. Enforced hematopoietic cell E- and L-selectin ligand (HCELL) expression primes transendothelial migration of human mesenchymal stem cells. Proc Natl Acad Sci U S A, 2011, 108(6): 2258-2263.
66. Wu M, Ji S, Xiao S, et al. JAM-A promotes wound healing by enhancing both homing and secretion activities of mesenchymal stem cells. Clin Sci (Lond), 2015, 129(7): 575-588.
67. Li Q, Zhang A, Tao C, et al. The role of SDF-1-CXCR4/CXCR7 axis in biological behaviors of adipose tissue-derived mesenchymal stem cells in vitro. Biochem Biophys Res Commun, 2013, 441(3): 675-680.
68. Francois M, Romieu-Mourez R, Li M, et al. Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther, 2011, 20(1): 187-195.
69. Xu S, Menu E, De Becker A, et al. Bone marrow-derived mesenchymal stromal cells are attracted by multiple myeloma cell-produced chemokine CCL25 and favor myeloma cell growth in vitro and in vivo. Stem Cells, 2012, 30(2): 266-279.
70. Won YW, Patel AN, Bull DA. Cell surface engineering to enhance mesenchymal stem cell migration toward an SDF-1 gradient. Biomaterials, 2014, 35(21): 5627-5635.
71. De Becker A, Riet IV. Homing and migration of mesenchymal stromal cells: how to improve the efficacy of cell therapy? World J Stem Cells, 2016, 8(3): 73-87.
72. Lalu M, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One, 2012, 7(10): e47559.
73. von Bahr L, Batsis I, Moll G, et al. Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. Stem Cells, 2012, 30(7): 1575-1578.
74. Liu R, Wei S, Chen J, et al. Mesenchymal stem cells in lung cancer tumor microenvironment: their biological properties, influence on tumor growth and therapeutic implications. Cancer Lett, 2014, 353(2): 145-152.
75. Vulcano F, Milazzo L, Ciccarelli C, et al. Wharton's jelly mesenchymal stromal cells have contrasting effects on proliferation and phenotype of cancer stem cells from different subtypes of lung cancer. Exp Cell Res, 2016, 345(2): 190-198.
76. Nystedt J, Anderson H, Tikkanen J, et al. Cell surface structures influence lung clearance rate of systemically infused mesenchymal stromal cells. Stem Cells, 2013, 31(2): 317-326.
77. Pilz GA, Ulrich C, Ruh M, et al. Human term placenta-derived mesenchymal stromal cells are less prone to osteogenic differentiation than bone marrow-derived mesenchymal stromal cells. Stem Cells Dev, 2011, 20(4): 635-646.
78. Elahi KC, Klein G, Avci-Adali M, et al. Human mesenchymal stromal cells from different sources diverge in their expression of cell surface proteins and display distinct differentiation patterns. Stem Cells Int, 2016: 5646384.
79. Rolandsson Enes S, Andersson Sj?land A, Skog I, et al. MSC from fetal and adult lungs possess lung-specific properties compared to bone marrow-derived MSC. Sci Rep, 2016, 6: 29160.
80. Strioga M, Viswanathan S, Darinskas A, et al. Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. Stem Cells Dev, 2012, 21(14): 2724-2752.

Previous Article
支氣管擴張的診斷和治療進展
Next Article
2016 年美國胸科學會年會重癥哮喘最新研究進展

Chinese Journal of Respiratory and Critical Care Medicine

間充質干細胞治療急性呼吸窘迫綜合征的研究進展及相關問題

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content